Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
出版年份 2016 全文链接
标题
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
作者
关键词
Chemorefractory advanced gastric cancer, Tyrosine kinase inhibitor, Sunitinib, FOLFIRI, VEGF
出版物
BMC CANCER
Volume 16, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-08-31
DOI
10.1186/s12885-016-2736-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma
- (2015) Do Joong Park et al. ANNALS OF SURGICAL ONCOLOGY
- Angiogenic and growth factors in gastric cancer
- (2015) Susanne Blank et al. JOURNAL OF SURGICAL RESEARCH
- Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation
- (2015) Alessia Brossa et al. Oncotarget
- Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
- (2014) Sanne de Haas et al. ANGIOGENESIS
- Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection
- (2014) Xuefei Wang et al. CANCER SCIENCE
- Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
- (2014) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data
- (2014) Klaus Mross et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
- (2014) Kerri-Ann Norton et al. OncoTargets and Therapy
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
- (2013) G. Collet et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
- (2013) Esther Cidon et al. Cancers
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
- (2011) N. Starling et al. ANNALS OF ONCOLOGY
- Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
- (2011) M. Moehler et al. CURRENT CANCER DRUG TARGETS
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis
- (2011) Jieer Ying et al. MEDICAL ONCOLOGY
- Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
- (2011) Eun Kyoung Jeon et al. Cancer Research and Treatment
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
- (2010) F Fei et al. LEUKEMIA
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started